Literature DB >> 8284567

Radical surgery for abdominal neuroblastoma.

E M Kiely1.   

Abstract

Radical operation predominantly for those with stages III and IV, i.e., locally advanced and/or metastatic abdominal neuroblastoma, is described. Generally the surgery has been performed when tumour shrinkage has been achieved by means of chemotherapy, and metastases have been ablated. The author compares his results in 46 patients with those of 34 patients undergoing less aggressive surgery performed by a number of surgeons, with similar results. Given the difficulties inherent in performing curative resection for disseminated abdominal neuroblastoma, the surgeon needs to be convinced that his/her efforts are worthwhile. The results reported here do not provide such reassurance.

Entities:  

Mesh:

Year:  1993        PMID: 8284567     DOI: 10.1002/ssu.2980090606

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  5 in total

1.  A long-term follow-up of residual mass neuroblastoma in a patient with cystic fibrosis.

Authors:  Aldo Naselli; Federico Cresta; Federica Favilli; Rosaria Casciaro
Journal:  BMJ Case Rep       Date:  2015-01-05

Review 2.  Neuroblastoma.

Authors:  S Shah; Y Ravindranath
Journal:  Indian J Pediatr       Date:  1998 Sep-Oct       Impact factor: 1.967

3.  Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma.

Authors:  Daniel von Allmen; Andrew M Davidoff; Wendy B London; Collin Van Ryn; Daphne A Haas-Kogan; Susan G Kreissman; Geetika Khanna; Nancy Rosen; Julie R Park; Michael P La Quaglia
Journal:  J Clin Oncol       Date:  2016-11-21       Impact factor: 44.544

Review 4.  The role of surgery in the treatment of neuroblastoma.

Authors:  Masayuki Kubota
Journal:  Surg Today       Date:  2010-05-23       Impact factor: 2.549

5.  Neuroblastoma: treatment outcome after incomplete resection of primary tumors.

Authors:  Suk-Bae Moon; Kwi-Won Park; Sung-Eun Jung; Woong-Jae Youn
Journal:  Pediatr Surg Int       Date:  2009-07-21       Impact factor: 1.827

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.